Selective Laser Trabeculoplasty (SLT) is an advanced, non-invasive, primary or secondary treatment for raised intraocular pressure (IOP) in glaucoma. It uses short laser pulses of a specific wavelength to selectively target pigmented trabecular meshwork cells without causing widespread thermal damage. Standard SLT utilises a low-energy laser with a short pulse duration of 3-5 ns. This low-energy irradiation stimulates removal of damaged cells by macrophages and increases trabecular network porosity to restore effective aqueous outflow through the drainage angle. This results in the reduction of IOP to non pathologic levels.
The OptoSLT nano offers a shorter-than-standard laser pulse duration of just 1 ns, with advanced technology in the form of a more stable and efficient solid-state diode-pumped laser technology, thus offering a quicker and safer SLT treatment option. THE FIRST DIODE PUMPED SOLID STATE LASER DEVICE ON TH MARKET FOR SLT The OptoSLT nano is a new laser technology that is superior to existing SLT devices on the market. It offers very high pulse to pulse stability (±2.5%). By reducing laser pulse duration to 1 ns without compromising efficacy outcomes, this new technology permits faster (up to 5 Hz) and safer SLT procedures (improved pulse energy repeatability during SLT). With a compact, highly portable design, the OptoSLT nano is an ideal addition to every doctor’s practice.The device’s energy levels range from 0.2 to 2.0 mJ and its red diode 635 nm aiming beam ensures precise focusing for highly predictive and effective treatment each and every time.